About Targazyme

About company

Targazyme, Inc. (formerly America Stem Cell, Inc.) is a clinical-stage biopharmaceutical company developing and commercializing breakthrough products designed to improve outcomes for patients receiving cell therapy. Our most advanced product, TZ101, improves the therapeutic potential of cells by enhancing migration to selective sites in the body and improving retention in tissue. This will increase the effectiveness of the cells in numerous disease indications. Target indications for the Company’s products include cancer, ischemic diseases like heart failure, critical limb ischemia and diabetic retinopathy, and radiation sickness, each of which represents a large market with significant opportunity to improve outcomes for patients. The company was founded in 2005 and has received funding from angel investors, the management team, and several non-profit and governmental institutions.